The science behind Isomark focuses on changes in the ratio of carbon isotopes in exhaled breath, which can be used as biomarkers of metabolic change. Measurements of the isotopic abundance of 13C are typically expressed as a relative change in the ratio of 13C/12C that is referred to as the Breath Delta Value, or BDV.

The technology has been refined by Isomark over the past 10 years with funding from grants, investors, and the State of Wisconsin. Founded in 2005 by University of Wisconsin researchers, Isomark’s initial focus is in the early detection of severe infections and a patient’s response to treatment. Through ongoing research and clinical studies, Isomark has additional pending patents related to response to treatment and energy balance. Excitingly the new energy balance patent covers market expansion into the unregulated market of fitness and weight management.  The technology has evolved through years of animal research followed by ongoing human clinical studies.

Clinical Studies

CANARY00Single center proof-of-concept study in adult and pediatric ICUs to evaluate baseline variability of BDV and infection correlationPilot/Phase I
CANARY01Multi-center trial to estimate the positive and negative predictive values the breath delta value in at risk patientsPhase II
CANARY02Multi-center trial to evaluate the efficacy of the Canary monitor in at risk patientsRegulatory Phase III
NUTR PILOTSingle Center Pilot study to assess clinical applicability of technology in the supplementally fed patientsPilot/Phase I
NUTR101Single center efficacy trial comparing to Canary monitor to metabolic cart testingPhase II
METFAST02Metabolic Fasting Study with Industry Leader in Fitness to test intermittent fasting for fitness goalsPilot/Phase I
ATHLETICS01Single center Pilot study to evaluate the efficacy of the SmartBurn™ technology on this platformPilot/Phase I